Gemini Therapeutics CTO Scott Lauder resigns effective September 17, 2021

Disc Medicine, Inc.

Dr. Scott Lauder, Ph.D., notified Gemini Therapeutics of his resignation as Chief Technology Officer on Sept 7, 2021.
Resignation effective September 17, 2021; no replacement announced.
Company states departure is not due to any disagreement with the Company or Board.
Company thanks Dr. Lauder for his years of service and contributions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Lauder

Chief Technology Officer

IRON · Disc Medicine, Inc.

Effective: 2021-09-17
Filed: September 9, 2021, 7:59 PM ET

On September 7, 2021, Dr. Scott Lauder, Ph.D. informed the Company of his intent to resign as Chief Technology Officer, effective as of September 17, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Lauder resigned as Chief Technology Officer at Disc Medicine, Inc..

Action: resigned
Role: Chief Technology Officer

Exact text from the filing

On September 7, 2021, Dr. Scott Lauder, Ph.D. informed the Company of his intent to resign as Chief Technology Officer, effective as of September 17, 2021.

View on SEC.gov

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-268317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.